Aegis Capital Starts NephroGenex, Inc. (NRX) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. GOOGL
8. GMAB
9. BBIO
10. BETR

Go back to Aegis Capital Starts NephroGenex, Inc. (NRX) at Buy

Aegis Starts NephroGenex (NRX) at Buy; Diabetic Nephropathy is 'Significant' Unmet Need

June 17, 2014 9:34 AM EDT

Aegis Capital starts coverage on NephroGenex (Nasdaq: NRX) at Buy with an 18-month target price of $25.

Analyst Ram Selvaraju sees NephroGenex having a significant market opportunity. The analyst commented, In our view, diabetic nephropathy constitutes an appealing market niche, since this represents a significant unmet medical... More